Methylprednisolone Sodium Succinate for Injection 40mg. 10vials/Box

Product Details
Customization: Available
Dosage Form: Powder Injection
Dossier: Ready
Still deciding? Get samples of US$ 0.1/Piece
Request Sample
Manufacturer/Factory, Trading Company, Group Corporation
Gold Member Since 2018

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Importers and Exporters
The supplier has import and export rights
to see all verified strength labels (7)
  • Methylprednisolone Sodium Succinate for Injection 40mg. 10vials/Box
  • Methylprednisolone Sodium Succinate for Injection 40mg. 10vials/Box
  • Methylprednisolone Sodium Succinate for Injection 40mg. 10vials/Box
  • Methylprednisolone Sodium Succinate for Injection 40mg. 10vials/Box
  • Methylprednisolone Sodium Succinate for Injection 40mg. 10vials/Box
  • Methylprednisolone Sodium Succinate for Injection 40mg. 10vials/Box
Find Similar Products

Basic Info.

Model NO.
Powder Injection
Usfda
Ready
Transport Package
Carton
Specification
40mg
Trademark
Sinolead
Origin
China

Product Description

Methylprednisolone Sodium Succinate for Injection 40mg. 10vials/BoxMethylprednisolone Sodium Succinate for Injection 40mg. 10vials/Box
Basic Info.

 
Generic Name Methylprednisolone Sodium Succinate For Injection 40mg
Strength 40mg
Packing 10vials/box
Origin China

Component:
Methylprednisolone Sodium Succinate For Injection 40mg.

Character:
This product is white to white - like loose mass or powder.

Indications:

Unless used as an alternative treatment for certain endocrine disorders, glucocorticoids are only a symptomatic treatment.

1. Anti-inflammatory therapy: - Rheumatic diseases: as an adjunct for short-term use (to help patients through the acute or critical phase) for: post-traumatic osteoarthritis; Synovitis due to osteoarthritis; Rheumatoid arthritis, including juvenile rheumatoid arthritis (individual patients may require low-dose maintenance therapy); Acute or subacute bursitis; Superior malleolitis; Acute nonspecificity.

2. Immunosuppressive therapy: organ transplantation.

3. Treatment of hematologic diseases and tumors: - Hematologic diseases: acquired (autoimmune) hemolytic anemia; Adult spontaneous thrombocytopenic purpura (intravenous injection only allowed, intramuscular injection contraindicated); Adult secondary thrombocytopenia; Hypoerythroblast (erythrocyte anemia); Congenital hypoplastic anemia. - Cancer: palliative care for: adult leukaemia and lymphoma; Acute leukemia in children.

4. Therapeutic shock: Shock induced by adrenal cortical insufficiency or shock that does not respond to conventional treatment due to adrenal cortical insufficiency (hydrocortisone is commonly used; Methylprednisolone can be used if you do not wish to have halocorticoid activity). Hemorrhagic, traumatic, and surgical shock that did not respond to conventional treatment. Although there are no well-developed (double-blind controlled) clinical studies, data from animal studies suggest that Miloxone (r) may be effective in treating shock that does not respond to conventional therapy (e.g., rehydration). Also see "Septic Shock" in the "Precautions" section.

5. Others: - Nervous system: cerebral edema due to primary or metastatic tumors, and/or surgery and radiotherapy; Traumatic cerebral edema; Acute critical stage of multiple sclerosis; Treatment for acute spinal cord injury should begin within 8 hours after trauma. - In conjunction with appropriate antituberculous chemotherapy for tuberculous meningitis with subarachnoid obstruction or tending to obstruction. Trichinosis involving the nerves or heart muscle. - Prevent nausea and vomiting caused by cancer chemotherapy.

6. Endocrine disorders: primary or secondary adrenal cortical insufficiency; Acute adrenocortical insufficiency; (Hydrocortisone or cortisone is the preferred drug for these diseases. Synthetic glucocorticoids can be used in combination with corticosteroids if necessary.) In patients known to have or likely to have adrenal cortical insufficiency, medication is given in the event of severe trauma or disease. Congenital adrenal hyperplasia; Nonsuppurative thyroiditis; Hypercalcemia due to cancer.

 

Usage and dosage:

As an adjunct to life threatening conditions: The recommended dose is 15 to 30mg/kg BW for at least 30 minutes intravenously. Depending on clinical needs, this dose can be repeated in the hospital every 4-6 hours over a 48-hour period.


Precautions:

Systemic adverse reactions may be observed. Although rarely seen during short-term treatment, careful follow-up is warranted. This is part of the follow-up for steroid therapy and is not specific to any particular drug. Possible adverse effects of glucocorticoids (e.g., methylprednisolone) are: fluid and electrolyte disturbances: equivalent to cortisone and hydrocortisone, synthetic derivatives (e.g., methylprednisolone) have less salocorticoid effects.
Methylprednisolone Sodium Succinate for Injection 40mg. 10vials/Box

Methylprednisolone Sodium Succinate for Injection 40mg. 10vials/BoxMethylprednisolone Sodium Succinate for Injection 40mg. 10vials/BoxMethylprednisolone Sodium Succinate for Injection 40mg. 10vials/BoxMethylprednisolone Sodium Succinate for Injection 40mg. 10vials/BoxMethylprednisolone Sodium Succinate for Injection 40mg. 10vials/BoxMethylprednisolone Sodium Succinate for Injection 40mg. 10vials/Box

Methylprednisolone Sodium Succinate for Injection 40mg. 10vials/BoxMethylprednisolone Sodium Succinate for Injection 40mg. 10vials/BoxMethylprednisolone Sodium Succinate for Injection 40mg. 10vials/Box

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier